Neurophet acquires Singaporean certification for Alzheimer's diagnosis

South Korea's medical imaging device maker Neurophet said on Tuesday that its SCALE PET has obtained a medical device certification from the Health Sciences Authority of Singapore (HSA).

It won certifications in a total of four countries, starting in Korea in February this year, followed by the United States and Japan, and Singapore most recently.

Neurophet's SCALE PET is a software program that quantitatively analyzes Alzheimer's biomarkers by combining positron emission tomography (PET) imaging and magnetic resonance imaging (MRI).

It then provides the levels of amyloid beta protein deposition in regions of the brain.

Prior to earning the certification, the company had signed an agreement with Nanyang Technological University's Dementia Research Center for joint research on brain imaging analysis.

Combining local data held by the center and Neurophet's brain imaging analysis solutions, the two parties will cooperate in joint clinical research and paper publications.

Currently, Neurophet is also set to apply for an HSA certification for another flagship product called "Neurophet AQUA," the cerebral nerve degeneration image analysis software.

"With the certification, our company will be able to move into the Singaporean medical device market," adding, "Given Singapore is the hub of Southeast Asia's medical device market, it gave us a foothold to advance into neighboring countries," Neurophet CEO Bin Joon-gil said.

Write to Jeong Min Nam at peux@hankyung.com